Drug company to offer cheaper opioid overdose treatment after hiking price 600 percent

A drug company is offering a significantly cheaper version of its life-saving opioid overdose treatment after a Senate investigation found that it spiked the price of its drug.

A report from the Senate’s Permanent Subcommittee on Investigations last month found that the company, Kaléo, hiked the price of its drug Evzio to $4,100 for two injectors, raising the price by more than 600 percent between 2014 and 2017.

ADVERTISEMENT
After this scrutiny, the company on Wednesday announced that it will offer a cheaper generic version of the drug for $178 for two injectors.

Evzio is an auto-injector form of the drug naloxone, which is a key part of fighting the opioid crisis.

“With approximately 130 people dying daily from opioid overdoses, we recognize that more needs to be done to improve access for patients,” said Spencer Williamson, president and CEO of Kaléo.

The investigation last month was led by Sens. Rob PortmanRobert (Rob) Jones PortmanGOP reasserts NATO support after report on Trump’s wavering Leaders nix recess with no shutdown deal in sight Senators restart shutdown talks — and quickly hit roadblocks MORE (R-Ohio) and Tom CarperThomas (Tom) Richard CarperEPA's Wheeler faces grilling over rule rollbacks Overnight Energy: House votes to reopen Interior, EPA | Dems question EPA over Wheeler confirmation prep | Virginia Dem backs Green New Deal Dems ask why EPA is preparing for Wheeler confirmation during shutdown MORE (D-Del.).

“This news is a positive step forward and I’m hopeful that it will increase access to naloxone, a critically-important overdose reversal drug that has saved tens of thousands of lives,” Portman said after the company’s announcement on Wednesday.

Carper added that the episode should be a “teachable moment for other drug manufacturers.”